Immunotherapy plus chemo may turn inoperable esophageal cancer into surgical candidates
Disease control
Recruiting now
This Phase 2 trial is testing whether adding the immunotherapy drug tislelizumab to standard chemoradiotherapy can shrink advanced esophageal tumors enough to allow surgery. About 45 people with unresectable esophageal squamous cell carcinoma will receive the combination, followe…
Phase: PHASE2 • Sponsor: Ming-Yu Lien • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC